- Gene therapy, using T cells (HA-1 TCR) from a donor, to treat acute leukemia that has come back (relapsed) after getting an allogeneic (cells from a donor) blood or marrow transplant (BMT)
Previously featured trials:
- CAR T cells (CD33CART) to treat acute myeloid leukemia (AML) that has come back (relapsed) or has not gotten better with treatment (refractory) in children and young adults
- Donor Search Prognosis (DSP) score to help choose the best donor before allogeneic (cells from a donor) blood or marrow transplant (BMT)
- High Impact – Reviewers consider the potential impact on clinical practice, whether the research addresses a known issue or gap in care and more.
- Patient-Centered – Reviewers consider if travel costs for participants are paid for, if the informed consent is written in plain language, if results are shared with participants and more.
- Diversity, Equity and Inclusion Focus – Reviewers consider if the clinical trial staff are trained on cultural and anti-bias practices, the trial locations are in rural and urban areas and more.
- Accessibility – Reviewers consider if the eligibility criteria is as broad as possible, the requirements of participants seem reasonable for what they’re trying to study (e.g. there aren’t unnecessary labs or visits required), the number of trial locations and more.
- Data and Trial Design – Reviewers consider whether patient’s perspectives are collected (patient-reported outcomes), the quality of the data analysis (statistical framework) and more.